Use of human MIR421 in preparation of preparations for diagnosing and treating prostate cancer

• Main Authors: LI YAO, BAO SHENGLIN, YANG SHU, PU HONGLEI, WU HAI, JING FENGXIANG
• Format: Patent
• Language: Chinese; English
• Published: 01.02.2017
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention belongs to the biotechnical field, and concretely relates to a use of a new prostate cancer molecule marker microRNA 421 (MIR421) in the preparation of prostate cancer diagnosing and treating preparations and prostate cancer diagnosing kits. The use comprises the following steps: screening prostate cancer high-risk populations, diagnosing the prostate cancer, designing prostate cancer drug target, monitoring the prostate cancer treatment condition, and carrying out prognosis detection on the prostate cancer. A method using the molecule marker and a diagnostic kit containing the molecule marker to diagnose the prostate cancer has the characteristics of simplicity in operation, convenience in material drawing, good safety, no wounds, high specificity, high sensitivity, and easiness in massive screening. 本发明属于生物技术领域，具体涉及种新的前列腺癌分子标记物microRNA 421 (MIR421)在制备诊断及治疗前列腺癌诊断制剂及诊断试剂盒中的用途，包括前列腺癌高危人群的筛选，前列腺癌的诊断，前列腺癌药物靶标的设计，前列腺癌治疗状况的监测及前列腺癌预后检测等。使用该分子标记物及含有该分子标记物的诊断试剂盒诊断前列腺癌，操作简单、取材方便、安全无创伤，且具有较高的特异性和灵敏度及易于大量筛